Mohammad Rokon Uddin, Mohammad Abdul Matin, Mohammad Kamal Hossain Foraji and Baizid Hossain
This paper proposed an auto-configurable algorithm for wireless sensor network (WSN) to efficiently re-organize the network topology. The auto-configurable algorithm is based on self- configurable cellular architecture and it has been observed from simulation result that the proposed algorithm achieves lower power consumption than the existing one.
Shahinul Alam, SKM Nazmul Hasan, Golam Mustafa, Mahabubul Alam, Mohammad Kamal and Nooruddin Ahmad
Background and Objectives
To observe the effect of Pentoxifylline for 1 year on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis (NASH).
Materials and Methods
A single center, open label Randomized Control Trial. Patients were included if they had ultrasonographic evidence of fatty liver and nonalcoholic fatty liver disease activity score (NAS) ≥ 5 on liver histology. A total of 35 patients were selected; 25 of PL (Experimental) group and 10 of L (Control) group. PL group received 400 mg pentoxifylline thrice daily along with lifestyle modification and there was only lifestyle modification for the L group. After one year, NAS and fibrosis was compared in both groups.
In PL group, NAS improved 2.10 ± 1.07; whereas in L group, NAS was 0.90 ± 0.99 (P = 0.006). As per the protocol analysis, NAS ≥ 2 improved in 15/20 (75%) in PL group and in 3/10 (30%) in L group (P = 0.018). In PL group, the individual component of NAS, steatosis improved from 2.30 ± 0.66 to 0.95 ± 0.76 (P = 0.000), lobular inflammation from 1.65 ± 0.59 to 1.05 ± 0.51 (P = 0.002) and hepatocyte ballooning from 1.50 ± 0.51 to 1.30 ± 0.57 (P = 0.258). In L group, steatosis improved from 2.30 ± 0.68 to 1.40 ± 1.08 (P = 0.01), lobular inflammation and hepatocyte ballooning did not improve. The fibrosis score did not improve in any group. In PL group, NAS improved significantly (P = 0.027; OR=22.76, CI=1.43-362.40) independent of weight reduction.
Pentoxifylline for 1 year improves the hepatic histological activity but not fibrosis of NASH patients.